oral+semaglutide+approval The FDA has just approved the first GLP‑1 pill for obesity: a once‑daily oral semaglutide “Wegovy pill,” which offers weight loss similar to the injectable Wegovy and also reduces cardiovascular risk in Oral GLP-1 Wegovy chases approval

Cold intolerance is not listed among the common adverse effects in the Summary of Product Characteristics for semaglutide (Wegovy) or liraglutide (Saxenda), which typically include gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation), injection site reactions, and headache

Even though observational studies have shown some association between BS and microvascular complications, the RCTS comparing surgery to medical therapy for DM thus far have not establish a significant impact of BS in improving microvascular complications or delaying the progression of microvascular disease with DM

dovrebbero essere controllati settimanalmente fino alla stabilizzazione dei valori e successivamente mensilmente, nei pazienti che assumono anticoagulanti insieme a CARNITENE (vedere paragrafio 4.4)

The condition can also impede healthy digestion